title: Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients.
abstract: Patients with frontotemporal lobar degeneration (FTLD) present a profound personality change, social misconduct, overeating, and stereotyped behavior. We examined the hypothesis that many of the behavioral symptoms of FTLD will respond to selective serotonin reuptake inhibitors (SSRIs). Sixteen FTLD patients were treated with an SSRI (fluvoxamine maleate) in an open 12-week trial. Treatment responses for stereotyped behavior and other neurobehavioral symptoms were evaluated by the Stereotypy Rating Inventory and the Neuropsychiatric Inventory. The behavioral symptoms, especially stereotyped behaviors of FTLD, significantly improved after treatment. Randomized, placebo- and other SSRI-controlled trials may improve available treatments.
authors.affiliation: Department of Neuropsychiatry, Ehime University School of Medicine, Ehime, Japan. mikeda@m.ehime-u.ac.jp
authors.forename: Manabu
authors.initials: M
authors.lastname: Ikeda
authors.forename: Kazue
authors.initials: K
authors.lastname: Shigenobu
authors.forename: Ryuji
authors.initials: R
authors.lastname: Fukuhara
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Hokoishi
authors.forename: Naruhiko
authors.initials: N
authors.lastname: Maki
authors.forename: Akihiko
authors.initials: A
authors.lastname: Nebu
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Komori
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Tanabe
mesh_terms: D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001519:Behavior; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D005625:Frontal Lobe / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009410:Nerve Degeneration / Q000188:drug therapy* / Q000473:pathology; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales; D013702:Temporal Lobe / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016666:Fluvoxamine